Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001097 · ClinicalTrials.gov registry record
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
A clinical trial of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 120
- Enrollment target
- 20
- Study locations
NCT00001097: Completed study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001097 is a study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001097, a study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART. HIV infection weakens the immune system's ability to fight other infections and diseases. HAART is a type of anti-HIV therapy shown to improve the immune system of adults. However, not all patients show the same amount of improvement with HAART. Doctors believe that results may depend on how strong a patient's immune system is before starting HAART. Long-term effects of HAART in children and young adults have not yet been studied.
Conditions Studied
Study Locations (20)
Florida
- North Broward Hosp District - Fort Lauderdale
- Univ of Florida Gainesville - Gainesville
- Univ of Florida Health Science Ctr / Pediatrics - Jacksonville
- Univ of Miami (Pediatric) - Miami
- Palm Beach County Health Dept - Riviera Beach
California
- UCSD Med Ctr / Pediatrics / Clinical Sciences - La Jolla
- Children's Hosp of Los Angeles/UCLA Med Ctr - Los Angeles
- Los Angeles County - USC Med Ctr - Los Angeles
- Harbor - UCLA Med Ctr / UCLA School of Medicine - Los Angeles
Illinois
- Cook County Hosp - Chicago
- Univ of Illinois College of Medicine / Pediatrics - Chicago
- Chicago Children's Memorial Hosp - Chicago
- Univ of Chicago Children's Hosp - Chicago
Alabama
- Univ of Alabama at Birmingham - Pediatric - Birmingham
- Univ of South Alabama - Mobile
Arizona
- Phoenix Childrens Hosp - Phoenix
Colorado
- Children's Hosp of Denver - Denver
Connecticut
- Connecticut Children's Med Ctr - Farmington
District of Columbia
- Howard Univ Hosp - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1997-12 |
What the finished NCT00001097 record still lists
NCT00001097 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (73% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00001097 names 20 study sites across 9 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00001097 about?
NCT00001097 is a clinical study titled "Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems". The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART. HIV infection weakens the immune system's ability to fight other infect...
What is the current status of trial NCT00001097?
This trial is currently completed. The enrollment target is 120 participants. The study started on 1997-12.
What conditions does trial NCT00001097 study?
This clinical trial studies the following conditions: HIV Infections.
Who is sponsoring clinical trial NCT00001097?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001097 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001097's enrollment target sits among peer trials
120 239th of 542 higher than 295 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia